Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.
Lipids 2015 Conference is a must attend as it will provide an in depth view of world-class, interdisciplinary research discussion from basic science researchers through clinical investigators to become leaders in research on lipid metabolism and its relation to cardiovascular disease, diabetes, obesity, atherosclerosis, metabolic diseases, immunological diseases, and cancer etc.
The Injectable Drug Delivery Market by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices & Therapeutics [Diabetes & Oncology] - Global Forecasts to 2017, analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and Rest of the World. Global injectable drug delivery technologies market over the forecast period of 2012 to 2017. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012; it is expected to reach $43.3 billion by 2017 at a CAGR of 14.0% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. This market insight report on Liposomes gives an insight into global Liposomes market. The study also provides information regarding products and technologies in the field of Liposomes. Business profiles of 46 major companies are discussed in the report. The report covers more than 330 companies that are engaged in Liposomes research and supply of products and/or services. The global liposomes’ market is projected at a CAGR of 15%, through 2005-2015.
9th Indo Global Summit on Cancer Therapy November 02-04, 2015 Hyderabad, India ; 7th Global Summit on Cancer Therapy October 05-07, 2015 Dubai, UAE; 5th International Conference and Exhibition on Cell and Gene Therapy May 19-21, 2016 San Antonio, USA; 6th World Congress on Cell & Stem Cell Research February 29-March 02, 2016 Philadelphia, USA;6th International conference of Phospholipase A2 and Lipid Mediators (PLM2015), Shinjuku (a central downtown of Tokyo), Japan, 10-12 February 2015; 22-25 March 2016 Cardiolipin as Key Lipid of Mitochondria in Health and Disease, Florence, Italy, 30 September -1 October 2015; The XIX Lipid Meeting Leipzig, BIO CITY, Leipzig, Germany, 10-12 December 2015; Lipids and Health: Risk, Reward and Revelation, London, UK, 16-17 November 2015;
Understanding the mechanisms of intracellular trafficking and its interaction with other signaling molecules may lead to novel approaches in the treatment of a number of hematologic and other diseases. NIH has invested $127,980 in this specific area in 2015.
Lipid rafts/caveolae flask-shaped structures are rich in proteins as well as lipids such as cholesterol and sphingolipids and have several functions in signal transduction. They play a role in cancer cells development, endocytosis and the uptake of pathogenic bacteria and certain viruses. Studies that have helped to elucidate the role of lipid rafts in signaling via receptor tyrosine kinases and G protein-coupled receptors. Though the plasma membrane may contain microdomains with a variety of different lipid compositions, cholesterol and sphingolipid rich microdomains, named lipid rafts, have been the most intensely scrutinized. Rafts are postulated to regulate protein–protein interactions by laterally segregating proteins according to their affinity for ordered membrane domains. Cholesterol is an amphipathic molecule like phospholipid moiety and cholesterol plays an important role in maintaining the integrity of the membrane and is also involved with cell to cell signalling process.
Lipid phosphate phosphatases (LPPs) regulate cell signaling by modifying the concentrations of lipid phosphates versus their dephosphorylated metabolic intermediates. The extremely low aqueous solubility of long chain fatty acids (LCFA) together with the very high affinity of serum albumin and cytoplasmic fatty acid binding proteins for LCFA have challenged the limits of technology in resolving the individual steps of the process. Bioactive lipids, such as eicosanoids, endocannabinoids and lysophospholipids are endogenous signaling molecules with wide spectrum of pathophysiological functions in regulating cellular activities. Recent studies describes that lipid modification influences the movement of a signaling protein within the cell and its final destination. Nonvesicular transport could occur by transport of lipid monomers through the cytosol or by transfer of lipids at regions of close apposition between cell membranes. Several lipid transfer proteins and mutants defective in lipid transport have been identified and isolated, the precise roles of proteins in net transport and sorting of lipids remain unclear. G protein-coupled receptors (GPCRs) modulate diverse physiological and behavioral signaling pathways by virtue of changes in receptor activation and inactivation states.
4th International Conference on Integrative Biology July 18-20, 2016 Berlin, Germany; 3rd International Conference on Genomics & Pharmacogenomics September 21-23, 2015 San Antonio, USA; World Congress on Human Genetics October 31- November 02, 2016 Valencia, Spain; Unconventional Protein and Membrane Trafficking, Lecce, Italy 4—7 October 2016; 5th Leipzig Symposium, "Analytics and Technology" Leipzig, Germany, 9-10 March 2016; Organelle Crosstalk in Membrane Dynamics and Cell Signalling, Edinburgh, UK, 26-29 October 2015; GPCRs: Beyond Structure Towards Therapy, Monash University Prato Centre, Italy, 16-18 September 2015; Modeling Approaches in Molecular Signalling, University College London, UK, 13 November 2015;
International Conference on Protein Engineering October 26-28, 2015 Chicago, USA; World Congress on Amino Acids and Proteins December 08-09, 2016 Baltimore, USA; 2nd International Conference on Transcriptomics August 18-20, 2016 Portland, Oregon USA; International Conference on Next Generation Sequencing July 21-22, 2016 Berlin; International Symposium on Lipid Oxidation and Antioxidants5-7 June 2016, Porto, Portugal, Membrane Proteins From A to Z, University of Leeds, UK. 16-17 December 2015; Phosphatases and Signalling in Health and Disease, University of Bath, UK, 20-22 June 2016; Leucine Rich Repeat Kinase 2: Ten Years Along the Road to Therapeutic Intervention, Henley Business School, UK, 11-13 July 2016;
The total cost of reducing low-density lipoprotein includes the costs of physician services, lifestyle counseling, screening, case finding and monitoring, dietary and exercise modifications, medications, and treating side effects. The annual cost of statin drugs to reduce low-density lipoprotein cholesterol levels can range from $1,082 to $1,543 per year. The cost of follow-up or treatment-related appointments varies by type of provider, location, and practice setting. Although the cost of reducing low-density lipoprotein cholesterol levels can be high, it is much lower than the direct and indirect costs of cardiovascular disease.
In 2002, the National Cholesterol Education Program (NCEP) panel found that, on the basis of current retail prices for lipid-lowering drugs, low-density lipoprotein-lowering drug therapy is highly cost-effective for persons with established coronary heart disease (including a prior coronary heart disease event); cost-effective for the primary prevention of coronary heart disease in persons with a coronary heart disease risk equivalent (the person does not have coronary heart disease but does have an absolute 10-year risk of developing major coronary events, such as myocardial infarction and coronary death, equal to that of persons with coronary heart disease), and those at high risk for coronary heart disease; and acceptable for the primary prevention of coronary heart disease in persons whose 10-year risk of "hard coronary heart disease" (heart attack and death from coronary heart disease) is between 10% and 20%.
The National Cholesterol Education Program recommends using dietary therapy, which is more cost-effective than low-density lipoprotein-lowering drugs, as the first-line therapy in persons with a 10-year risk of coronary heart disease that is less than 10% per year.
Elevated plasma triglycerides and very-low-density lipoproteins are directly associated with the risk of atherosclerotic heart disease, although not as independent risk factors. In contrast, high levels of high-density lipoprotein cholesterol have been found to be a protective factor for the development of that disease, so that decreased levels constitute a risk factor. Atherosclerosis is characterized by vascular obstruction from the deposits of plaque, resulting in reduced blood flow. Plasma lipoproteins have traditionally been grouped into five major classes, based on their buoyant density: chylomicrons, very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). Since lipids are not soluble in blood, they are transported as lipoproteins after reaction with water-soluble proteins in the blood. Lipids in the blood are absorbed by liver cells to provide energy for cellular functions. Excess lipids in the blood are eventually converted into adipose tissue. Abnormally high levels of triglycerides and cholesterol are thought to be involved in hardening of the arteries. In nondiabetic persons of normal weight, administration of insulin leads to an increase in glucose up- take by insulin-sensitive tissues, inhibition of lipolysis, and a decrease in serum levels of free fatty acids. However, in insulin-resistant states accompanied by hyperinsulinemia, such as occur in obesity and type II diabetes, there is resistance to results in increased fat breakdown and increased serum levels of free fatty acids and glycerol. The increased glycerol resulting from lipolysis tends to drive gluconeogenesis by mass effect, thereby leading to increased glucose production by the liver, further contributing to hyperglycemia. Lipid storage diseases are a group of inherited metabolic disorders in which harmful amounts of fatty materials (lipids) accumulate in various tissues and cells in the body. Lipid storage diseases are inherited from one or both parents who carry a defective gene.
4th International Conference on Translational Medicine October 26-28, 2015 Baltimore, Maryland, USA; 4th International Conference and Exhibition on Nutrition October 26-28, 2015 Chicago, Illinois, USA; International Conference on Epilepsy & Treatment September 21-22, 2015 Baltimore, USA; Lipid and Lipoprotein Metabolism in Chronic Disease Pathogenesis and Treatment, June 12-17, 2016 Waterville Valley, NH; 57th International Conference on the Bioscience of Lipids, Chamonix, France, September 23 - 27, 2016; Recent Advances in Lipoprotein Physiology and Related Disease, Waterville Valley, NH, June 11-12, 2016;
The economic burden of lipid disorders is substantial because of the impact of lipid levels on the risk of cardiovascular disease and coronary heart disease events. The direct and indirect costs of all types of cardiovascular disease in 2015 were estimated to be $706.2 billion. The cost of cardiovascular disease exceeds that of any other high-cost medical conditions. For example, in 2008, the estimated total cost of all cancers was $228 billion and in 2007, the cost attributable to diabetes mellitus was $174 billion.
Heart disease and stroke are not only a major cause of premature death in persons younger than 65 years but also are major causes of serious disability in the United States. The indirect costs of cardiovascular disease, including those related to lost productivity, are enormous. It is estimated that the indirect cost of cardiovascular disease will total more than $279.1 billion in 2014.
The cost of implementing a lipid screening program varies by location, provider base, method of screening, which cholesterol measurements are taken, and other factors. The average cost of a single cholesterol or lipid profile test is relatively low but the cumulative costs of screening can be substantial, especially if all recommended screening and follow-up procedures are followed. In 2008, the private-sector cost of annual visits to lower LDLcholesterol averaged $74 per session.
Coronary heart disease is recognized to be the cause of death for 80% of people with diabetes. Diabetes is treatable, but even when glucose levels are under control it greatly increases the risk of heart disease and stroke. High blood pressure has long been recognized as a major risk factor for cardiovascular disease. Obesity is a major risk factor for cardiovascular disease and has been strongly associated with insulin resistance. Physical inactivity is another modifiable major risk factor for insulin resistance and cardiovascular disease. Fish, plant, and nut oils are the primary dietary source of omega-3 fatty acids. Omega-3 fatty acids are cardioprotective mainly due to beneficial effects on arrhythmias, atherosclerosis, inflammation, and thrombosis. The latest dietary guidelines call for five to thirteen servings of fruits and vegetables a day (2½ to 6½ cups per day), depending on one’s caloric intake. Another constant threat comes from nasty chemicals called free radicals. They are capable of damaging cells and genetic material. The most familiar ones are vitamin C, vitamin E, beta-carotene, and other related carotenoids, along with the minerals selenium and manganese. Numerous clinical trials are underway testing a type of stem cell found in bone marrow, called mesenchymal stem cells or MSCs, to see if they are effective in treating the form of CHF that follows a heart attack. While those trials have shown some small improvements in patients the researchers have not found that the MSCs are creating replacement heart muscle. Most of these involve looking for ways to create stem cells that can replace the damaged heart muscle, restoring the heart’s ability to efficiently pump blood around the body.
6th International Conference on Clinical & Experimental Cardiology, November 30-December 02 2015, USA; 8th Global Cardiologists Annual Meeting, July 18-20 2016, Germany; International Conference on Interventional Cardilogy, September 12-14 2016, Germany; European Cardiology Congress, October 24-26 2016, Spain; 8th International Conference on Clinical & Experimental Cardiology, November 14-16 2016, California; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon; Hypertension 2015, September 16-19 2015, USA; 3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia
Today two-thirds of adults and nearly one-third of children struggle with overweight and obesity .If obesity rates stay consistent, by 2030, 51 percent of the population will be obese. Twenty years ago, no state had an obesity rate above 15 percent. Today there are 41 states with obesity rates over 25 percent, according to the Trust for American's Health. Since 1980, the rate of obesity in children and adolescents has almost tripled.72% of older men and 67% of older women are now overweight or obese. Obesity is linked to more than 60 chronic diseases. According to the American Cancer Society, 572,000 Americans die of cancer each year, about one-third of these cancer deaths are linked to excess body weight, poor nutrition and/or physical inactivity. Over 75 percent of hypertension cases are directly linked to obesity. Approximately two-thirds of U.S. adults with type 2 diabetes are overweight or have obesity
Obesity-associated arterial hypertension is characterized by activation of the sympathetic nervous system, activation of the renin-angiotensin system, and sodium retention, among other abnormalities. It is estimated that excess body weight, accounted for approximately 26% of cases of hypertension in men and 28% in women and for approximately 23% of cases of coronary heart disease in men and 15% in women. Obese individuals have an increase in fatty tissue that increases their vascular resistance and in turn increases the work the heart has to do to pump blood throughout the body. Indicators for risk of hypertension include obesity, abdominal obesity and weight gain.
Anti-hypertension medications should be started if hypertension is diagnosed. But, with weight-loss, a significant fall in blood pressure may permit a decrease in the number of medications taken or decrease the amount of medication taken. Prevention would be better than any drug.
Given the important pathophysiologic links between weight and hypertension described, a significant increase in the prevalence of hypertension in coming years could be expected, if trends of increasing weight in the population are not stabilized and reversed.
4th International Conference & Exhibition on Obesity & Weight Management, December 07-09 2015, USA; 5th International Conference & Exhibition on Obesity & Weight Management, December 05-07 2016,USA; 6th Global Healthcare & Fitness Summit, August 22-24 2016,USA; Global Summit & Expo on Healthcare, November 9-11 2015, UAE; 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension, November 05-07 2015, Turkey; British Hypertension Society Annual Scientific Meeting, September 21-23 2015, UK; Japanese Society of Hypertension 38th Annual Scientific Meeting, October 9-11 2015, Japan; Epigenetics, Obesity and Metabolism, October 11-14 2015, UK; 13th International Congress on Obesity, May 01-04 2016, Canada
In order to project the market size of iSONEP(A lipidomic strategic generated drug for blindness), we first estimate the current market size of its competitors. The current US sales volume of lipidomics suggests that about 800,000 doses were prescribed in 2012, which translates into ~130,000 patients (assuming six doses per year on average). The US preference for Avastin suggests that approximately 356,000 patients were treated in the same year. Eylea's sales volume translates into approximately 75,500 patients in 2012 (assuming bi-monthly injection). The total number of patients treated with these anti-VEGF drugs is thus about 561,000 in 2012. We assume a proportionate growth of the number of patients treated with anti-VEGF drugs with the total patient population.
The iSONEP is expected to launch in 2017. We project that in 2025 its market share will peak at 10% of the market currently captured by anti-VEGF drugs, and at 20% of the market currently not captured. We assume its cost to be $2,000 per dose, or $12,000 per year. Historical data suggest that a drug entering Phase II clinical trial has about 16% probability of eventual FDA approval. Taking all these into consideration and using a 20% discount rate, we project that iSONEP can contribute about 148.3 million USD to the NPV of the company, or $14.4 per share outstanding.
Lipidomics has been greatly facilitated by recent advances in, and novel applications of, electrospray ionization mass spectrometry (ESI/MS. Lipidomic studies play an essential role in defining the biochemical mechanisms of lipid-related disease processes through identifying alterations in cellular lipid metabolism, trafficking and homeostasis. The two major platforms currently used for lipidomic analyses are HPLC-MS and shotgun lipidomics. Recent expansion in research in the field of lipidomics has been driven by the development of new mass spectrometric tools and protocols for the identification and quantification of molecular lipids in complex matrices. The application of electrospray ionization to crude lipid extracts without prior fractionation-the so-called shotgun approach-is one such example, as it has perhaps been more successfully applied in lipidomics than in any other Recent technological advances in MS and chromatography have greatly enhanced the developments and applications of metabolic profiling of diverse lipids in complex biological samples. Lipidomics not only provide insights into the specific functions of lipid species in health and disease, but will also identify potential biomarkers for establishing preventive or therapeutic programs for human disease. Research is performed in one of more of six themes: 1) Mapping neurodegenerative lipidomes in models 2) High-throughput screening of underlying signalling mechanisms key regulators of lipid function 3) Identifying lipid-protein and lipid-lipid interactions that alter organelle or protein / lipid target function; 4) Characterizing and validating circulating lipid biomarkers 5) Identifying natural products and their active compounds that act as lipid modulators 6) Representing and statistically validating lipidomic changes, disseminating and communicating large datasets, developing hybrid biomedical representations and statistical models of neurodegenerative disease and Simulating effect of lipid metabolism (computational modeling).
3rd International Conference on Genomics & Pharmacogenomics September 21-23, 2015 San Antonio, USA, International Conference on Glycomics December 01-03, 2016 Chicago, USA ; 5th International Conference and Exhibition on Metabolomics May 16-18, 2016 Osaka, Japan; 6th International Conference and Exhibition on Metabolomics November 28-30, 2016 Atlanta, USA; 5th European Lipidomic Meeting, Sept 2-4, 2015, Swansea, UK; 11th GERLI Lipidomics Meeting, "Lipids in Agronomy, Health and Disease" , October 25-28, 2015, Bischoffsheim, France; LIPID MAPS Annual Meeting 2016: Lipidomics Impact on Metabolic, Cancer, Cardiovascular and Inflammatory Diseases , May 17 - 18, 2016, La Jolla, CA, USA;